EUR/USD likely to find a peak near 1.25: UBS
WATERTOWN, MA—Ellen Chiniara, Chief Legal Officer at Kymera Therapeutics, Inc. (NASDAQ:KYMR), recently executed a series of stock transactions, according to a filing with the Securities and Exchange Commission. The transactions come as the stock has declined about 15% in the past week and is trading near its 52-week low of $29.16. On March 3, Chiniara sold a total of 2,241 shares of Kymera’s common stock, with the transactions ranging in price from $30.3271 to $31.0046 per share, amounting to $68,239 in total.
In addition to these sales, Chiniara acquired 27,500 restricted stock units and 55,000 stock options, both at no cost. The restricted stock units are set to vest in three equal annual installments, while the stock options will vest in thirty-six equal monthly installments, contingent upon her continued employment with the company. According to InvestingPro data, Kymera maintains a strong liquidity position with a current ratio of 7.53, indicating ample resources to meet short-term obligations.
These transactions were part of routine financial management, including sales to cover tax obligations related to the vesting of restricted stock units. Following these transactions, Chiniara holds 80,085 shares of Kymera’s common stock directly. For comprehensive insider trading analysis and 12 additional key insights about Kymera, visit InvestingPro.
In other recent news, Kymera Therapeutics reported fourth quarter 2024 financial results that did not meet analyst expectations, with a loss of $0.88 per share, compared to the forecasted $0.77 loss per share. Revenue for the quarter was $7.39 million, significantly lower than the anticipated $14.71 million. The decline in collaboration revenues, attributed to their partnership with Sanofi (NASDAQ:SNY), was also notable, dropping from $47.9 million in the previous year to $7.4 million. Despite these figures, Kymera maintains a strong financial position with $851 million in cash reserves, projected to support operations until mid-2027.
H.C. Wainwright adjusted their price target for Kymera to $54.00 from $60.00, while maintaining a Buy rating, indicating a cautious yet optimistic outlook on the company’s clinical trials. Meanwhile, Truist Securities reaffirmed their Buy rating and $53.00 price target, expressing confidence in Kymera’s technology and management. The company has also introduced a new performance stock unit plan aimed at aligning employee incentives with clinical success. Kymera plans to advance several clinical trials, including the Phase 1 study of their STAT6 degrader, KT-621, with data expected in June 2025.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.